Tesamorelin 2mg

Tesamorelin and visceral-fat research

Tesamorelin 2mg is a modified 44-amino-acid analogue of growth hormone-releasing hormone. It stimulates the GH/IGF-I axis and has been studied extensively in adults with HIV-associated abdominal fat accumulation.

A focus on fat around internal organs

Visceral adipose tissue surrounds abdominal organs and differs from the subcutaneous fat beneath the skin. This distinction is central to tesamorelin research: a randomised trial found reductions in visceral fat without the same pattern of change in limb or abdominal subcutaneous fat.

The trial's extension phase examined whether those changes persisted. Participants continuing treatment maintained further visceral-fat reductions, while those switched to placebo lost the initial improvement. This provides useful information about both the response and its dependence on continued exposure in that clinical setting.

Broader metabolic questions

A smaller randomised study investigated liver fat as well as visceral fat and reported reductions in both. Together, these studies support a focused discussion of regional fat distribution and endocrine regulation, rather than general slimming.

Tesamorelin is the active ingredient in Egrifta medicines, but this research vial is not identified as a branded formulation. The clinical evidence is population- and formulation-specific; the 2mg catalogue amount alone does not establish interchangeability with a medicine.

Also known as / branded as

• Egrifta (brand family of tesamorelin medicines)
• Egrifta SV (specific medicine formulation)
• Egrifta WR (specific medicine formulation)